[heavyweight] the first batch of price linkage! 4 + 7 non pilot cities; 14 varieties of the next round of fierce competition

Hebei, a non "4 + 7" city, breaks the game! Tangshan and Qinhuangdao will take the lead in launching the 4 + 7 linkage A few days ago, according to the news of "gathering south medicine", on April 16, 2019, Tangshan City and Qinhuangdao medical insurance bureau held a meeting, which will launch the 4 + 7 linkage between the two cities The specific rules are still under study, but it is still uncertain The medical insurance bureau still hopes to support the selected enterprises and strive to launch the 4 + 7 linkage as soon as possible However, this is not the first time that Tangshan City in Hebei Province has mentioned 4 + 7 centralized mining As early as March 6, at the key work of medical insurance and precise poverty alleviation scheduling meeting in Tangshan City, Hebei Province, "explore to promote centralized procurement with volume and reduce the price of drug consumables", which was also proposed as the key work of medical insurance in 2019 According to the deployment, Tangshan medical insurance department will play a "combination fist" in drug bidding and purchase: 1 On the basis of including 17 kinds of anticancer drugs into the medical insurance catalog, monitor the payment and use through the information system; 2 Actively explore and utilize the "4 + 7" volume procurement results; 3 Find out the base number of drugs used by hospitals above the second level in the city, select the good drugs with large dosage, good effect and patients' preference, purchase with the help of the provincial platform, and strive to reduce the price of drug consumables, so that the common people can get benefits Hebei follows up the 4 + 7 price linkage or "expected" according to the statistics of the Ministry of Commerce, in 2015, the total sales volume of seven categories of medical products in Beijing was 138 billion, that in Tianjin was 51.9 billion, that in Hebei was 45.1 billion, the total market volume would reach 235 billion, and the total sales volume of seven categories of medical products in China was 1661.3 billion, accounting for about 1 / 7 of the national medical market The huge "dividend" of pharmaceutical purchasing makes it have the right to speak with manufacturers in price negotiation Moreover, in recent years, there have been large medical consumables or drug purchase alliances in China, such as Sanming, ten western provinces and regions, Shanghai, Jiangsu, Zhejiang, Anhui and Fujian Cross regional joint purchase has become a trend Through the way of quantity with price, the prices of drugs and consumables are reduced Beijing, Tianjin and Hebei are also one of the collection combinations At the end of 2016, Beijing Tianjin Hebei health and Family Planning Commission signed the framework agreement on joint procurement of medical consumables for Beijing Tianjin Hebei public hospitals From the point of view of the procurement of medical consumables in three areas, its benefits are very obvious In May last year, the health and Family Planning Commission of Beijing, Tianjin and Hebei jointly held a press conference to report the completion of the procurement of joint medical consumables, which mentioned that after the implementation of the results of joint procurement, the procurement cost of consumables for the three public hospitals could be saved by more than 800 million yuan per year, with an overall decrease of 15% The three regions have made great achievements in the joint procurement of medical consumables Hebei, Beijing and Tianjin have formed a certain "tacit agreement" in the mode of centralized procurement According to this idea, Hebei may have the "inherent advantage" of following up 4 + 7 in drug procurement, whether it is negotiation, formulating supporting policies, carrying out pilot work, etc The first round of 4 + 7 centralized mining has achieved initial results These non pilot areas will be shortlisted On April 16, the Information Office of the State Council will hold a regular briefing on the State Council's policies At the meeting, Mr Chen Jinfu, deputy director of the State Medical Security Bureau, introduced the centralized purchase of drugs and the work of medical assistance He pointed out that on April 1, 11 pilot cities had started the centralized purchase As of 24:00 on April 14, the total purchase amount of 25 selected varieties in 11 pilot areas reached 438 million pieces, 533 million yuan in total, 27.31% of the total agreed purchase amount, which exceeded the pre-set amount It also dispels the worries of the past The quality and supply of the winning drugs have been guaranteed, and the amount of drugs used has exceeded expectations Relevant policies have been basically fully implemented, such as prepayment of medical insurance, hospital use and payment collection, etc On April 3, Premier Li Keqiang presided over the executive meeting of the State Council, which emphasized the need to further promote the pilot of national drug centralized procurement, the monitoring and response of drug shortage and medical assistance, earnestly summarize the experience of the pilot, and push it forward in a timely and comprehensive manner Therefore, on the basis of the initial results of the above-mentioned 4 + 7 centralized procurement work, the process of comprehensively pushing forward the national drug centralized procurement pilot may be accelerated, gradually expanding the pilot area, bidding products, and improving supporting policies At present, there have been many documents indicating direct or indirect follow-up of 4 + 7 centralized mining, such as Liaoning, Jiangxi, Fujian, Sichuan, Guangdong and other places In addition, Xie Bing, chairman of China's biopharmaceutical board of directors, said that the second batch of "4 + 7" with volume procurement varieties is expected to be announced this summer and implemented at the end of this year In view of this, the industry figures speculate that according to the idea of selecting the first batch of 4 + 7 pilot cities for centralized mining, 4 municipalities directly under the central government and 7 sub provincial cities are all regional central cities in China, and they have strong local financial resources, which is the first stop for the implementation of local policies In the second round belt quantity procurement, the state may give priority to the sub provincial cities, such as Hangzhou, Ningbo, Nanjing, Wuhan, Harbin, Jinan, Qingdao, etc Since the second batch of 4 + 7 centralized purchase, the competition of 14 varieties is well known to the public From 2014 to 2017, Shanghai has carried out three times of volume purchase, with a total of 42 varieties achieving substantial price reduction, with a maximum decline of 64% To some extent, the 4 + 7 centralized purchase refers to the successful experience of volume purchase in Shanghai According to the experience of Shanghai, products with large dosage, wide clinical use, more qualified enterprises and existing overseas markets are preferred However, products with exclusive varieties, small purchase volume, shortage of drugs and narrow therapeutic window are not likely to be shortlisted In addition, referring to the first batch of 4 + 7 winning products, there are two or more enterprises that have been evaluated, such as rosuvastatin calcium tablets, tenofovir dipivoxil fumarate tablets, irbesartan tablets, etc., which are highly competitive So, in the second round of 4 + 7 centralized purchase, which products that have been evaluated are the most competitive? According to the statistics of "weekly trend of consistency evaluation: 5 varieties have been evaluated, 7 varieties have been undertaken; Kelun, Fosun, Qilu and Renfu...", as of April 11, there were 1040 acceptance numbers of CDE acceptance consistency evaluation (318 varieties of 338 enterprises, calculated according to supplementary application), of which 182 acceptance numbers (86 varieties) have passed Among them, there are more than 2 enterprises that have been evaluated for 14 varieties, more than 3 enterprises that have been evaluated for products such as metformin hydrochloride tablets, Amoxicillin Capsules, entecavir capsules, etc the competition is the biggest The specific situation is as follows: statement: this point of view only represents the author, not the position of the drug intelligence network, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.